332 related articles for article (PubMed ID: 8055960)
1. Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor. Involvement of individual cysteine-rich repeats.
Corcoran AE; Barrett K; Turner M; Brown A; Kissonerghis AM; Gadnell M; Gray PW; Chernajovsky Y; Feldmann M
Eur J Biochem; 1994 Aug; 223(3):831-40. PubMed ID: 8055960
[TBL] [Abstract][Full Text] [Related]
2. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
[TBL] [Abstract][Full Text] [Related]
3. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins.
Scallon BJ; Trinh H; Nedelman M; Brennan FM; Feldmann M; Ghrayeb J
Cytokine; 1995 Nov; 7(8):759-70. PubMed ID: 8664442
[TBL] [Abstract][Full Text] [Related]
4. Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding.
Marsters SA; Frutkin AD; Simpson NJ; Fendly BM; Ashkenazi A
J Biol Chem; 1992 Mar; 267(9):5747-50. PubMed ID: 1313418
[TBL] [Abstract][Full Text] [Related]
5. In vitro comparison of inhibiting ability of soluble TNF receptor p75 (TBP II) vs. soluble TNF receptor p55 (TBP I) against TNF-alpha and TNF-beta.
Terlizzese M; Simoni P; Antonetti F
J Interferon Cytokine Res; 1996 Dec; 16(12):1047-53. PubMed ID: 8974008
[TBL] [Abstract][Full Text] [Related]
6. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H
Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
[TBL] [Abstract][Full Text] [Related]
7. Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity.
Bigda J; Beletsky I; Brakebusch C; Varfolomeev Y; Engelmann H; Bigda J; Holtmann H; Wallach D
J Exp Med; 1994 Aug; 180(2):445-60. PubMed ID: 7519237
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75.
Sheehan KC; Pinckard JK; Arthur CD; Dehner LP; Goeddel DV; Schreiber RD
J Exp Med; 1995 Feb; 181(2):607-17. PubMed ID: 7836916
[TBL] [Abstract][Full Text] [Related]
9. Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells.
Pinckard JK; Sheehan KC; Schreiber RD
J Biol Chem; 1997 Apr; 272(16):10784-9. PubMed ID: 9099731
[TBL] [Abstract][Full Text] [Related]
10. Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily.
Gruss HJ
Int J Clin Lab Res; 1996; 26(3):143-59. PubMed ID: 8905447
[TBL] [Abstract][Full Text] [Related]
11. Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects.
Medvedev AE; Espevik T; Ranges G; Sundan A
J Biol Chem; 1996 Apr; 271(16):9778-84. PubMed ID: 8621658
[TBL] [Abstract][Full Text] [Related]
12. Differential expression and ligand binding properties of tumor necrosis factor receptor chimeric mutants.
Hsu KC; Chao MV
J Biol Chem; 1993 Aug; 268(22):16430-6. PubMed ID: 8393862
[TBL] [Abstract][Full Text] [Related]
13. Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.
Browning JL; Dougas I; Ngam-ek A; Bourdon PR; Ehrenfels BN; Miatkowski K; Zafari M; Yampaglia AM; Lawton P; Meier W
J Immunol; 1995 Jan; 154(1):33-46. PubMed ID: 7995952
[TBL] [Abstract][Full Text] [Related]
14. Activation of the TNF alpha-p55 receptor induces myocyte proliferation and modulates agonist-evoked calcium transients in cultured human tracheal smooth muscle cells.
Amrani Y; Panettieri RA; Frossard N; Bronner C
Am J Respir Cell Mol Biol; 1996 Jul; 15(1):55-63. PubMed ID: 8679222
[TBL] [Abstract][Full Text] [Related]
15. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor.
Nophar Y; Kemper O; Brakebusch C; Englemann H; Zwang R; Aderka D; Holtmann H; Wallach D
EMBO J; 1990 Oct; 9(10):3269-78. PubMed ID: 1698610
[TBL] [Abstract][Full Text] [Related]
16. A lymphotoxin-beta-specific receptor.
Crowe PD; VanArsdale TL; Walter BN; Ware CF; Hession C; Ehrenfels B; Browning JL; Din WS; Goodwin RG; Smith CA
Science; 1994 Apr; 264(5159):707-10. PubMed ID: 8171323
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors.
Frishman JI; Edwards CK; Sonnenberg MG; Kohno T; Cohen AM; Dinarello CA
J Infect Dis; 2000 Dec; 182(6):1722-30. PubMed ID: 11069245
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.
Warzocha K; Bienvenu J; Coiffier B; Salles G
Eur Cytokine Netw; 1995; 6(2):83-96. PubMed ID: 7578992
[TBL] [Abstract][Full Text] [Related]
19. A family of ligands for the TNF receptor superfamily.
Cosman D
Stem Cells; 1994 Sep; 12(5):440-55. PubMed ID: 7528588
[TBL] [Abstract][Full Text] [Related]
20. The three HveA receptor ligands, gD, LT-alpha and LIGHT bind to distinct sites on HveA.
Sarrias MR; Whitbeck JC; Rooney I; Ware CF; Eisenberg RJ; Cohen GH; Lambris JD
Mol Immunol; 2000 Aug; 37(11):665-73. PubMed ID: 11164894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
